Pancreatic cancer and nutrition (CROSBI ID 308486)
Prilog u časopisu | pregledni rad (stručni) | međunarodna recenzija
Podaci o odgovornosti
Mužina, Dubravka ; Zovak, Mario ; Čiček, Slaven
engleski
Pancreatic cancer and nutrition
Although there was a progress in surgical and oncological treatment of pancreatic cancer in a recent decade, pancreatic cancer remains a disease with a dismal prognosis, with 5-year survival of only 5 percent. Operable pancreatic cancer patients have better prognosis (around 25 percent are still alive after 5 years), but most of the patients are inoperable at the time of diagnosis. Considering low operability and higher tendency for weight loss and tumor-induced systemic inflammation, pancreatic cancer patients have high incidence of cachexia. Cachexia in cancer patients is associated with lower quality of life, shorter survival and lower tolerance of anti-tumor therapy. All pancreatic cancer patients, both with operable, inoperable or disseminated disease, should be screened and treated for cachexia. Nowadays, treatment of cachexia should me multimodal and multidisciplinary.
cachexia ; malignant neoplasms ; enteral nutrition
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano